221 related articles for article (PubMed ID: 23432006)
1. Toxicity of magnetic resonance imaging agents: small molecule and nanoparticle.
Chang Y; Lee GH; Kim TJ; Chae KS
Curr Top Med Chem; 2013; 13(4):434-45. PubMed ID: 23432006
[TBL] [Abstract][Full Text] [Related]
2. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
Gupta A; Shamseddin MK; Khaira A
Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
[TBL] [Abstract][Full Text] [Related]
3. NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.
Ashouri H; Riyahi Alam N; Khoobi M; Haghgoo S; Rasouli Z; Gholami M
Magn Reson Imaging; 2024 Apr; 107():120-129. PubMed ID: 38215955
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
Weinreb JC; Abu-Alfa AK
J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
[TBL] [Abstract][Full Text] [Related]
5. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
Heverhagen JT; Krombach GA; Gizewski E
Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
[TBL] [Abstract][Full Text] [Related]
6. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis: the need for accurate case reporting.
Spinazzi A; Kirchin MA; Pirovano G
J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
[No Abstract] [Full Text] [Related]
8. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
Dawson P
J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
[No Abstract] [Full Text] [Related]
9. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
Jikki PN
J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
[No Abstract] [Full Text] [Related]
11. Focus on contrast-associated nephrogenic systemic fibrosis.
Partain CL
J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
[No Abstract] [Full Text] [Related]
12. Special issue: nephrogenic systemic fibrosis.
Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
[No Abstract] [Full Text] [Related]
13. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
Stratta P; Canavese C; Quaglia M; Fenoglio R
Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
[No Abstract] [Full Text] [Related]
14. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
[No Abstract] [Full Text] [Related]
15. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
Wang SC
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
[No Abstract] [Full Text] [Related]
17. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium-based contrast agents and NSF: evidence from animal experience.
Sieber MA; Steger-Hartmann T; Lengsfeld P; Pietsch H
J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis: history and epidemiology.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
[TBL] [Abstract][Full Text] [Related]
20. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
Abraham JL; Edward M
AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
